摘要：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整
编者按：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。（注：因官网未公布详细作者单位，如有遗漏或错误，欢迎留言指正。）
为深度报道此次盛会，《肿瘤瞭望》特此开设“瞭望联播”专栏，并荣幸邀请到江苏省人民医院殷咏梅教授担任特邀观察员。在会议期间，殷教授将连线SABCS现场的中国专家——复旦大学附属肿瘤医院张剑教授、浙江大学医学院附属第一医院傅佩芬教授、复旦大学附属肿瘤医院李俊杰教授、中山大学孙逸仙纪念医院刘强教授（按预计连线日期排序），每日实时传递会议的重磅研究成果与亮点发现。诚邀各位读者密切关注“瞭望联播”和《肿瘤瞭望》推出的栏目，共同见证SABCS大会的最新前沿进展，洞悉乳腺癌研究领域的未来趋势！
Poster Session 5
日期：12月13日
时间：12:30～2:00 p.m.
地点：Halls 2-3
P5-01-04: Determination and clinical characteristics of bone pseudoprogression on Advanced first-line therapy in metastatic breast cancer
转移性乳腺癌一线治疗中骨假性进展的确定和临床特征
报告作者：Yuan Yuan
P5-01-05: Clinicopathological features and outcomes of ERlow/HER2-low expression in de novo metastatic breast cancer: a preliminary cohort study
初发转移性乳腺癌ER低表达/ HER2低表达的临床病理特征和预后：一项初步队列研究
报告作者：Chongxi Ren
P5-01-16: m6A reader YTHDF3 promotes epithelial-mesenchymal transition and metastasis through facilitating Notch2 translation in breast cancer
m6A解读器YTHDF3通过促进Notch2翻译促进乳腺癌上皮-间质转化和转移
报告作者：Hong-Yu Chen
P5-01-24: PPFIA4 mediates glucose metabolism reprogramming to alter the biological characteristics of breast cancer
PPFIA4通过介导糖代谢重编程改变乳腺癌的生物学特性
报告作者：Haochen Yu
P5-01-25: Romidepsin Targets HDAC1/2 to Induce Ferroptosis in TNBC Enhancing Chemosensitivity to Eribulin
Romidepsin靶向HDAC1/2诱导TNBC的铁死亡增强对艾立布林的化疗敏感性
报告作者：Weipeng ZHAO
P5-01-29: Development of a Novel Antigen Presentation Assay in Triple-negative Breast Cancer
三阴性乳腺癌新型抗原呈递检测方法的开发
报告作者：Mei Li
P5-02-24: Targeting FOXK2 signaling in breast cancers with FOXK2 amplification/overexpression and PIK3CA oncogenic mutations: a promising therapeutic strategy?
靶向FOXK2信号通路在具有FOXK2扩增/过表达和PIK3CA致癌突变的乳腺癌：一个有前景的治疗策略？
报告作者：Hong Zhang
P5-03-13: Trastuzumab emtansine versus disitamab vedotin for HER2-positive metastatic breast cancer: a multicenter retrospective real-world study
比较恩美曲妥珠单抗与维迪西妥单抗治疗HER2阳性转移性乳腺癌：一项多中心回顾性真实世界研究
报告作者：Huihui Li
P5-03-14: Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in firstline/second-line setting
含inetetamab方案在HER2阳性转移性乳腺癌患者一线/二线治疗中的疗效和安全性
报告作者：Yuxin Mu
P5-03-25: Trastuzumab deruxtecan (T-DXd) in leptomeningeal metastases from HER2-altered cancers
T-DXd治疗HER2突变癌症患者的软脑膜转移
报告作者：Qian Ma
P5-03-27: Updated Real-World Evidence on the Efficacy and Safety of Inetetamab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Previously Treated with Trastuzumab
基于inetetamab治疗曲妥珠单抗治疗过的HER2阳性转移性乳腺癌患者有效性和安全性的最新真实世界证据
报告作者：Yangyang Duan
P5-04-16: Stromal tumor-infiltrating lymphocytes-based model predicts efficacy for neoadjuvant therapy in HER2-low early breast cancer
基于间质瘤浸润淋巴细胞的模型预测HER2低表达早期乳腺癌新辅助治疗的疗效
报告作者：Zhuxi Duan
P5-04-18: Clinical Validation of an Ultra-Sensitive ctDNA NGS Assay in HR-Positive, HER2-Negative Breast Cancer Patients
超敏感ctDNA NGS检测在HR阳性/HER2阴性乳腺癌患者中的临床验证
报告作者：Haoran Tang
P5-04-22: Prognostic value of circulating tumor DNA (ctDNA) in early triple-negative breast cancer (TNBC): A systematic review and meta-analysis
循环肿瘤DNA（ctDNA）在早期三阴性乳腺癌（TNBC）中的预后价值：一项系统综述和荟萃分析
报告作者：Diana Zhang
P5-04-25: Detection of Human Epidermal Growth Factor receptor 2 (HER2) in Cultured Circulating Tumor Cells (CTCs) Isolated from Peripheral Blood of Breast Cancer Patients
从乳腺癌患者外周血分离培养的循环肿瘤细胞（ctc）中人类表皮生长因子受体2 （HER2）的检测
报告作者：Ying Chang
P5-04-26: Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study
应用仅肿瘤靶向测序的924例台湾乳腺癌检测中BRCA1、BRCA2和PALB2基因组改变的患病率：来自VGH-TAYLOR研究的扩展数据分析
报告作者：Han Fang Cheng
P5-05-02: Pharmacokinetic profile and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial
下一代靶向HER2的ADC GQ1001联合吡咯替尼治疗既往接受过治疗的HER2阳性转移性乳腺癌患者的药代动力学特征和初步疗效：一项1b期临床试验
报告作者：Biyun Wang
P5-05-07: A prospective, multicenter, single-arm clinical study of inetetamab combined with pyrotinib and capecitabine/vinorelbine in the treatment of HER2-positive metastatic breast cancer resistant to previous trastuzumab treatment
inetetamab联合吡咯替尼和卡培他滨/长春瑞滨治疗曲妥珠单抗耐药的HER2阳性转移性乳腺癌的前瞻性、多中心、单臂临床研究
报告作者：Yan Xue
P5-05-08: Inetetamab-base regimens for patients with HER2- positive metastatic breast cancer and brain metastases: a realworld retrospective study
以inetetamab为基础的方案治疗HER2阳性转移性乳腺癌和脑转移患者：一项真实世界回顾性研究
报告作者：Liping Chen
P5-05-09: Trastuzumab deruxtecan combined with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: an exploratory, multi-center, single-arm, phase Ib/II study (TROPHY)
德曲妥珠单抗联合吡咯替尼一线治疗HER2阳性不可切除或转移性乳腺癌：一项探索性、多中心、单组、Ib/II期研究（TROPHY）
报告作者：Ying Fan
P5-05-12: Real-world outcome of patients with HER2-positive metastatic breast cancer who were treated with inetetamabcontaining regimens: A multicenter retrospective analysis conducted in China
含inetetamab方案治疗HER2阳性转移性乳腺癌患者的真实世界结局：一项中国多中心回顾性分析
报告作者：Huihui Li
P5-05-14: Real-World Treatment Patterns and Clinical Outcomes of Inetetamab combined with pyrotinib plus chemotherapy in Her-2 negative metastatic breast cancer patients : a multi-center retrospective study
HER2阴性转移性乳腺癌患者Inetetamab联合吡咯替尼联合化疗的真实世界治疗模式和临床结局：一项多中心回顾性研究
报告作者：Huanhuan Zhou
P5-05-16: Real-world analysis of inetetamab-based therapy for the treatment of HER2-positive advanced breast cancer.
基于inetetamab治疗HER2阳性晚期乳腺癌的真实世界分析
报告作者：Cailing Lin
P5-05-17: Trastuzumab deruxtecan for HER2-positive and HER2- low breast cancer brain metastasis: Results from a singleinstitution retrospective study.
德曲妥珠单抗治疗HER2阳性和HER2低表达的乳腺癌脑转移：一项单机构回顾性研究结果
报告作者：Chunfang Hao
P5-05-22: ARX788 for patients with HER2-positive advanced breast cancer: characterization, time course, and monitoring and management of adverse event from the phase III ACE-Breast-02 study
ARX788治疗HER2阳性晚期乳腺癌患者：ACE-Breast-02 III期研究的特征、时间进程以及不良事件的监测和管理
报告作者：Jian Zhang
P5-05-24: RC48-ADC (Disitamab vedotin, a HER2-directed antibody-drug conjugate) in Combination with Pyrotinib for Trastuzumab-treated HER2-Positive Recurrent or Metastatic Breast Cancer: A Phase Ib/II Study
RC48-ADC （Diitamab vedotin，一种靶向HER2的抗体-药物偶联物）联合吡咯替尼治疗曲妥珠单抗经治的HER2阳性复发或转移性乳腺癌：一项Ib/II期研究
报告作者：Xinrui Liang
P5-05-29: Real-world efficacy and safety of inetetamab-based therapy in patients with HER2- positive metastatic breast cancer with prior trastuzumab exposure: A prospective real-world study
在曲妥珠单抗暴露的HER2阳性转移性乳腺癌患者中，基于inetetamab的治疗的真实世界疗效和安全性：一项前瞻性真实世界研究
报告作者：Dedian Chen
P5-06-12: BreastSubtypeR: Streamlining Intrinsic Molecular Subtyping in Breast Cancer Research with a User-Friendly R Package
BreastSubtypeR：采用用户友好的R包简化乳腺癌研究中的内在分子亚型
报告作者：qiao yang
P5-06-13: ARRB1 cooperates with estrogen receptor to drive endocrine resistance in ER-positive breast cancer
ARRB1与雌激素受体合作驱动ER阳性乳腺癌的内分泌耐药
报告作者：Qian Xu
P5-06-16: Preclinical Characterization of LAE118, a Novel Allosteric Pan-mutant Selective PI3Ka Inhibitor
新型全突变型变构选择性PI3Ka抑制剂LAE118的临床前特征
报告作者：Ming Li
P5-06-27: OXTR inhibits breast cancer cell invasion and metastasis by regulating the post-translational modification of the COL1A1 protein to accelerate its degradation through the lysosomal pathway.
OXTR通过调控COL1A1蛋白的翻译后修饰，加速其通过溶酶体途径降解，从而抑制乳腺癌细胞的侵袭和转移
报告作者：Qing Shao
P5-07-03: Patient-Reported Outcomes Following Various Breast Reconstruction Techniques: A Retrospective Cohort Study in China
不同乳房重建技术后患者报告的结局：一项中国回顾性队列研究
报告作者：Hongmei Zheng
P5-07-04: Postoperative upper Limb Edema and Dysfunction Generated by axillary nodes Excision in breast cancer patients with high or low proportion of upper limb venous reflux(PLEDGEReflux): a multicenter, prospective cohort study
高比例或低比例上肢静脉回流（PLEDGEReflux）的乳腺癌患者腋窝淋巴结切除术后上肢水肿和功能障碍：一项多中心、前瞻性队列研究
报告作者：Qianrui Xu
P5-07-08: The ACOSOG Z0011 criteria can be safely applied to Chinese patients: the SAHZU experience
ACOSOG Z0011标准可安全应用于中国患者：SAHZU经验
报告作者：Yue Hu
P5-07-14: Clinical study of 99mTc-Rituximab combined with dyes double tracing for axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer
99mtc -利妥昔单抗联合染料双示踪用于乳腺癌新辅助化疗后腋窝前哨淋巴结活检的临床研究
报告作者：Hui Zhang
P5-07-19: A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in Human Epidermal Growth Factor Receptor 2 positive (HER2+) early breast cancer (EBC) in China: NER-Tree study—An interim analysis on safety
探讨奈拉替尼在中国人表皮生长因子受体2阳性（HER2+）早期乳腺癌（EBC）治疗模式的多中心、前瞻性、非干预性研究：NER-Tree研究——安全性中期分析
报告作者：Jin Zhang
P5-07-20: A prospective, open-label, single-arm phase II clinical study of inetetamab in combination w/ pyrotinib & albuminbound paclitaxel for neoadjuvant treatment of patients with HER2+ early & locally advanced breast cancer: updates on clinical trial
伊尼妥单抗联合吡咯替尼和白蛋白结合型紫杉醇用于HER2+早期和局部晚期乳腺癌患者新辅助治疗的前瞻性、开放标签、单臂II期临床研究：临床试验更新
报告作者：Nanlin Li
P5-07-23: Efficacy and Safety of Pyrotinib Combined with Trastuzumab and Aromatase Inhibitor in Neoadjuvant Treatment of HER2+/HR+ Breast Cancer: A Single-Arm, Multi-Center Phase II Exploratory Study
吡咯替尼联合曲妥珠单抗和芳香化酶抑制剂用于HER2+/HR+乳腺癌新辅助治疗的有效性和安全性：一项单组、多中心ⅱ期探索性研究
报告作者：Jie Ge
P5-07-27: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Updated results from a phase 1 study
BL-B01D1是首创的EGFRxHER3双特异性抗体-药物偶联物，用于局部晚期或转移性乳腺癌和其他实体瘤患者：一项I期研究的更新结果
报告作者：Jiong Wu
P5-08-06: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide (TCX) versus anthracycline plus docetaxel & cyclophosphamide regimen (TAC) in women with high-risk,Her2-negative breast cancer: an open-label, randomized controlled trial
卡培他滨联合多西他赛和环磷酰胺（TCX）对比蒽环类联合多西他赛和环磷酰胺（TAC）方案治疗高危HER2阴性乳腺癌：一项开放标签、随机对照试验
报告作者：Yu Song
P5-08-21: Analysis of factors influencing the efficacy of NAC and prognosis between HER2-0 and HER2-low HR negative breast cancer
HER2-0与HER2-low的HR阴性乳腺癌新辅助化疗疗效及预后的影响因素分析
报告作者：Jingjing Liu
P5-08-24: Prognostic Value of the Geriatric Vulnerability Score in Older Patients with Metastatic Breast Cancer
老年脆弱性评分在老年转移性乳腺癌患者中的预后价值
报告作者：Min Xiao
P5-09-03: Localization combined with multidetector CT 3- dimensional image reconstruction guided precision breast conserving surgery versus conventional breast conserving surgery: cosmetic analysis of the single center, prospective, cohort study.
定位联合多层螺旋CT三维图像重建引导精准保乳手术与传统保乳手术比较：单中心、前瞻性、队列研究的美容分析
报告作者：Yiqin Xia
P5-09-19: Survival outcomes of carboplatin plus taxanes neoadjuvant chemotherapy in triple negative breast cancer and cell-free DNA whole methylome based biomarker analysis: A prospective multi-center cohort study
卡铂联合紫杉类新辅助化疗对三阴性乳腺癌的生存结果和基于游离DNA全甲基化组的生物标志物分析：一项前瞻性多中心队列研究
报告作者：Xi Chen
P5-09-28: A phase I, prospective exploratory clinical study of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for patients with HR-positive, HER2-positive early or locally advanced breast cancer
一项对HR阳性/HER2阳性早期或局部晚期乳腺癌患者进行吡咯替尼+曲妥珠单抗、达尔西利和来曲唑新辅助治疗的I期、前瞻性探索性临床研究
报告作者：Guangdong Qiao, Yizi Cong
P5-09-29: Trastuzumab Combined with Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in NonPathological Complete Response HER2-Positive Early Breast Cancer Following Neoadjuvant Therapy: A Multicenter Phase II Study
曲妥珠单抗联合吡咯替尼和卡培他滨作为新辅助治疗后非病理完全缓解的HER2阳性早期乳腺癌的术后辅助治疗：一项多中心II期研究
报告作者：Chuan Wang
P5-10-18: What to measure in Real-World Evidence (RWE) Studies: A Patient Informed Conceptual Disease Model in EarlyStage Breast Cancer
在真实世界证据（RWE）研究中测量什么：早期乳腺癌患者知情的概念疾病模型
报告作者：Xiaoqing Xi
P5-10-21: Efficacy and safety of utidelone plus bevacizumab in the treatment of patients with Her2- metastatic breast cancer study
优替德隆联合贝伐珠单抗治疗HER2转移性乳腺癌的疗效和安全性研究
报告作者：Shaohua Zhang
P5-10-25: Exploring JAM2's Potential in Reducing Breast Cancer Invasiveness through IGF2BP2 Regulation
探索JAM2通过IGF2BP2调控降低乳腺癌侵袭的潜力
报告作者：Yang Peng
P5-11-07: A longitudinal analysis of the specific types of anxiety towards radiotherapy in patients with breast cancer before, during, and after radiotherapy
纵向分析乳腺癌患者在放疗前、中、后对放疗的具体焦虑类型
报告作者：Shi-Jia Wang
P5-11-11: Dual–responsive nanoprobe with oxygen economization capacity for potentiating synergistic–checkpointblockade–and–radiotherapy-radiodynamic therapy in breast cancer
具有节约氧气能力的双响应纳米探针可增强乳腺癌的协同-检查点阻断和放疗-放射动力学治疗
报告作者：Yueyang He
P5-11-14: Survival Outcomes of Breast Cancer Patients Underwent Neoadjuvant Radiotherapy vs. Adjuvant Radiotherapy: A Population-based Observational Study
乳腺癌患者接受新辅助放疗与辅助放疗的生存结局：一项基于人群的观察性研究
报告作者：Yue Huang
P5-12-15: Survival Nomogram Including Lymph Node Ratio for Patients with Invasive Micropapillary Breast Cancer
浸润性微乳头状乳腺癌患者包括淋巴结比率的生存列线图
报告作者：Yi-Zi Zheng
除5场Poster Session展示外，本届SABCS大会还特设14场Poster Spotlight Sessions，敬请关注相关题目和详细日程https://sabcs.org/FullProgram
▌Concurrent Poster Spotlight Sessions 1, 3-5, 7
Session 1: New Insights into Immune Biomarkers（免疫生物标志物的新见解）
时间：12月11日7:00 – 8:30 am
地点：Room 221ABC
主持人：David Rimm, Yale University
Session 3: Highlights on Novel Therapeutics（新型治疗亮点）
时间：12月11日7:00 – 8:30 am
地点：Stars at Night 1-2
主持人：Sara Tolaney, Dana-Farber Cancer Institute
Session 4: Prediction of Chemotherapy Response（化疗疗效预测）
时间：12月11日7:00 – 8:30 am
地点：Stars at Night 3-4
主持人：Sherene Loi, Peter Macallum Cancer Centre
Session 5: The Heart of the Matter - Improving Adverse Effects（核心问题-改善不良反应）
时间：12月11日7:00 – 8:30 am
地点：Hemisfair Ballroom 3
主持人：Anne Blaes, Masonic Cancer Center University of Minnesota
Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations（靶向ER和PI3K通路：新型药物和组合）
时间：12月11日7:00 – 8:30 am
地点：Hemisfair Ballroom 1-2
主持人：Shom Goel, Peter MacCallum Cancer Centre
▌Concurrent Poster Spotlight Sessions 2, 6, 8, 9 and 15
Session 2: Personalizing CDK 4/6 inhibitor therapy for patients with Metastatic Breast Cancer: Survival, QOL and biomarkers（转移性乳腺癌患者的个体化CDK 4/6抑制剂治疗：生存期、生活质量和生物标志物）
时间：12月12日7:00 – 8:30 am
地点：Hemisfair Ballroom 1-2
主持人：Lisa Carey, Lineberger Comprehensive Cancer Center University of North Carolina
Session 6: Locoregional Therapy（局部区域治疗）
时间：12月12日7:00 – 8:30 am
地点：Room 221ABC
主持人：Mylin Torres, Winshop Cancer Institute of Emory University
Session 8: Novel HER2 Therapeutics（新型HER2治疗）
时间：12月12日7:00 – 8:30 am
地点：Stars at Night 1-2
主持人：Ian Krop, Yale School of Medicine
Session 9: ctDNA uses for Minimal Residual Disease testing, tumor evolution, and novel technologies（ctDNA用于微小残留病检测、肿瘤进化和新技术）
时间：12月12日7:00 – 8:30 am
地点：Stars at Night 3-4
主持人：Charles Perou, Lineberger Comprehensive Cancer Center University of North Carolina
Session 15: Survivorship – Biomarker predictors and other survival-associated factors（生存-生物标志物预测和其他生存相关因素）
时间：12月12日7:00 – 8:30 am
地点：Room 221ABC
主持人：Lindsay Peterson, Washington University Siteman Cancer Center, St. Louis, Missouri
▌Concurrent Poster Spotlight Sessions 10-14
Session 10: Addressing Racial Disparities in Breast Cancer Outcomes（探讨乳腺癌结局的种族差异）
时间：12月13日7:00 – 8:30 am
地点：Hemisfair Ballroom 3
主持人：Yara Abdou, University of North Carolina School of Medicine
Session 11: Imaging to Guide Breast Cancer Treatment – Molecular Imaging and AI（影像学指导乳腺癌治疗——分子影像学和人工智能）
时间：12月13日7:00 – 8:30 am
地点：Hemisfair Ballroom 1-2
主持人：David Mankoff, Perelman School of Medicine University of Pennsylvania
Session 12: Immunobiology Impact on Therapeutic Efficacy（免疫生物学对治疗效果的影响）
时间：12月13日7:00 – 8:30 am
地点：Room 221ABC
主持人：Lajos Pusztai, Yale School of Medicine, New Haven, Connecticut
Session 13: Molecular determinants of therapeutic response and resistance - Spotight on CDK 4/6i and ADCs （治疗反应和耐药的分子决定因素——聚焦CDK4/6i和ADCs）
来源：肿瘤瞭望
